Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Neurochemical Pathology
|
January 1, 1985
Some enkephalin- or VIP-immunoreactive hippocampal pyramidal cells contain neurofibrillary tangles in the brains of aged humans and persons with Alzheimer's disease
H K Kulmala
Neuropathology and Applied Neurobiology
|
March 1, 1985
Immunocytochemical localization of enkephalin-like immunoreactivity in neurons of human hippocampal formation: effects of ageing and Alzheimer's disease
H K Kulmala
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
January 1, 1985
Role of the senile plaque in neuropeptide deficits of Alzheimer's disease
H K Kulmala, J T Hutton
Life Sciences
|
September 14, 1987
Behavioral suppression following 3,4-methylenenedioxymethamphetamine
H K Kulmala, J W Boja, M D Schechter
Brain Research Bulletin
|
May 1, 1987
A novel, adaptable and inexpensive computerized activity meter
H K Kulmala, J W Boja, J T Hutton
Life Sciences
|
April 27, 1981
Specific in vivo binding of 77Br-p-bromospiroperidol in rat brain: a potential tool for gamma ray imaging
H K Kulmala, C C Huang, R J Dinerstein, et al.
Experimental Aging Research
|
January 1, 1987
Brain reactive antibodies and the blood-brain barrier: observations in aging rodents and the effects of peripheral kainic acid
H K Kulmala, J W Boja, J W Albrecht, et al.
Biopharmaceutics & Drug Disposition
|
April 1, 1992
Pharmacokinetics of teicoplanin upon multiple dose intravenous administration to normal healthy male volunteers
G A Thompson, J A Smithers, M T Kenny, et al.
Antimicrobial Agents and Chemotherapy
|
January 1, 1992
Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers
J A Smithers, H K Kulmala, G A Thompson, et al.
Biopharmaceutics & Drug Disposition
|
November 1, 1992
Applicability of teicoplanin dosage adjustment guidelines for renally impaired patients over the range of 3 to 30 mg kg-1
J A Smithers, G A Thompson, M T Kenny, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Neurochemical Pathology
|
January 1, 1985
Some enkephalin- or VIP-immunoreactive hippocampal pyramidal cells contain neurofibrillary tangles in the brains of aged humans and persons with Alzheimer's disease
H K Kulmala
Neuropathology and Applied Neurobiology
|
March 1, 1985
Immunocytochemical localization of enkephalin-like immunoreactivity in neurons of human hippocampal formation: effects of ageing and Alzheimer's disease
H K Kulmala
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
January 1, 1985
Role of the senile plaque in neuropeptide deficits of Alzheimer's disease
H K Kulmala, J T Hutton
Life Sciences
|
September 14, 1987
Behavioral suppression following 3,4-methylenenedioxymethamphetamine
H K Kulmala, J W Boja, M D Schechter
Brain Research Bulletin
|
May 1, 1987
A novel, adaptable and inexpensive computerized activity meter
H K Kulmala, J W Boja, J T Hutton
Life Sciences
|
April 27, 1981
Specific in vivo binding of 77Br-p-bromospiroperidol in rat brain: a potential tool for gamma ray imaging
H K Kulmala, C C Huang, R J Dinerstein, et al.
Experimental Aging Research
|
January 1, 1987
Brain reactive antibodies and the blood-brain barrier: observations in aging rodents and the effects of peripheral kainic acid
H K Kulmala, J W Boja, J W Albrecht, et al.
Biopharmaceutics & Drug Disposition
|
April 1, 1992
Pharmacokinetics of teicoplanin upon multiple dose intravenous administration to normal healthy male volunteers
G A Thompson, J A Smithers, M T Kenny, et al.
Antimicrobial Agents and Chemotherapy
|
January 1, 1992
Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers
J A Smithers, H K Kulmala, G A Thompson, et al.
Biopharmaceutics & Drug Disposition
|
November 1, 1992
Applicability of teicoplanin dosage adjustment guidelines for renally impaired patients over the range of 3 to 30 mg kg-1
J A Smithers, G A Thompson, M T Kenny, et al.
Page
of 1